Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
07 2019
Historique:
received: 19 11 2018
revised: 04 04 2019
accepted: 25 04 2019
pubmed: 4 6 2019
medline: 25 2 2020
entrez: 3 6 2019
Statut: ppublish

Résumé

Hypoglycemia represents a relevant burden in people with diabetes. Consequences of hypoglycemia/fear of hypoglycemia on quality of life (QoL) and behaviors of patients with T1DM and T2DM were assessed. HYPOS-1 was an observational retrospective study. Fear of hypoglycemia (Fear of Hypoglycemia Questionnaire, FHQ), general health status (visual analog scale of EuroQol questionnaire, EQ5D-VAS) psychological well-being (WHO-5 well being index, WHO-5), diabetes related distress (Problem Areas in Diabetes 5, PAID-5), and corrective/preventive behaviors following hypoglycemia were compared between people with and without previous experience of severe and symptomatic hypoglycemia and by tertiles of FHQ scores. A multivariate analysis was performed to identify factors associated with the likelihood of being in the third tertile of FHQ score. Overall, 2229 patients were involved. Severe hypoglycemia had statistically significant and clinically relevant (measured as effect sizes) negative impact on EQ5D-VAS, WHO-5, PAID-5, and FHQ both in T1DM and T2DM. In T2DM, symptomatic episodes had similar impact of severe hypoglycemia. Moving from the first to the third FHQ tertile, lower scores of EQ-5D VAS and WHO-5, and higher levels of PAID-5 were found. Patients in the third tertile performed more frequently corrective/preventive actions that negatively impact on metabolic control. Previous hypoglycemia, insulin treatment, female gender, age, and school education were the independent factors associated with increased likelihood to be in the third tertile. Not only severe but also symptomatic hypoglycemia negatively affect patient QoL, especially in T2DM. Addressing fear of hypoglycemia should be a goal of diabetes education.

Sections du résumé

BACKGROUND AND AIMS
Hypoglycemia represents a relevant burden in people with diabetes. Consequences of hypoglycemia/fear of hypoglycemia on quality of life (QoL) and behaviors of patients with T1DM and T2DM were assessed.
METHODS AND RESULTS
HYPOS-1 was an observational retrospective study. Fear of hypoglycemia (Fear of Hypoglycemia Questionnaire, FHQ), general health status (visual analog scale of EuroQol questionnaire, EQ5D-VAS) psychological well-being (WHO-5 well being index, WHO-5), diabetes related distress (Problem Areas in Diabetes 5, PAID-5), and corrective/preventive behaviors following hypoglycemia were compared between people with and without previous experience of severe and symptomatic hypoglycemia and by tertiles of FHQ scores. A multivariate analysis was performed to identify factors associated with the likelihood of being in the third tertile of FHQ score. Overall, 2229 patients were involved. Severe hypoglycemia had statistically significant and clinically relevant (measured as effect sizes) negative impact on EQ5D-VAS, WHO-5, PAID-5, and FHQ both in T1DM and T2DM. In T2DM, symptomatic episodes had similar impact of severe hypoglycemia. Moving from the first to the third FHQ tertile, lower scores of EQ-5D VAS and WHO-5, and higher levels of PAID-5 were found. Patients in the third tertile performed more frequently corrective/preventive actions that negatively impact on metabolic control. Previous hypoglycemia, insulin treatment, female gender, age, and school education were the independent factors associated with increased likelihood to be in the third tertile.
CONCLUSION
Not only severe but also symptomatic hypoglycemia negatively affect patient QoL, especially in T2DM. Addressing fear of hypoglycemia should be a goal of diabetes education.

Identifiants

pubmed: 31153746
pii: S0939-4753(19)30126-7
doi: 10.1016/j.numecd.2019.04.009
pii:
doi:

Substances chimiques

Biomarkers 0
Blood Glucose 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

736-743

Investigateurs

R Fornengo (R)
E Nada (E)
A Ozzello (A)
L Sciangula (L)
N Musacchio (N)
G Marelli (G)
A Corsi (A)
F Baccetti (F)
V Paciotti (V)
R Iannarelli (R)
D Antenucci (D)
F Chiaramonte (F)
S Leotta (S)
S Gentile (S)
V Armentano (V)
F M Gentile (FM)
F Mastinu (F)
D Cucinotta (D)

Informations de copyright

Copyright © 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Auteurs

Maria Chiara Rossi (MC)

CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. Electronic address: rossi@coresearch.it.

Antonio Nicolucci (A)

CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.

Alessandro Ozzello (A)

Departmental Service of Diabetology and Metabolic Diseases, ASL TO3, Pinerolo, TO, Italy.

Sandro Gentile (S)

Campania University "Luigi Vanvitelli", Naples, Italy; Nefrocenter Research Network, Naples, Italy.

Alberto Aglialoro (A)

Metabolism and Diabetes Unit, Hospital St. Martin, Genoa, Italy.

Anna Chiambretti (A)

Metabolism and Diabetes Unit, ASL TO4, Chivasso, TO, Italy.

Fabio Baccetti (F)

Metabolism and Diabetes Unit, ASL 1, Massa, Carrara, Italy.

Francesco M Gentile (FM)

MEDIDIAB Metabolismo Endocrinologia Diabetologia, Bari, Italy.

Francesco Romeo (F)

Metabolism and Diabetes Unit, ASL TO5, Chieri, TO, Italy.

Giuseppe Lucisano (G)

CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.

Carlo B Giorda (CB)

Metabolism and Diabetes Unit, ASL TO5, Chieri, TO, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH